This case illustrates the potential of combining PD-1 inhibitors with HER2-targeted therapies to overcome resistance in HER2-positive gastric cancer, suggesting a promising treatment strategy for patients who do not respond to traditional therapies. The gene discussed is ERBB2; the disease is gastric cancer.